Výsledky vyhledávání

Final Results of a Non-Interventional Study Evaluating the Quality of Life in Second-line Treatment of Metastatic Renal Cell Carcinoma With Everolimus: The EVERPRO Study

Autor: Norbert Marschner, Christian Doehn, Anja Dietel, Katja Blumenstengel, Peter J. Goebell, Edwin Hermann, Anja Rogler, Marc-Oliver Grimm, Ulrich Kube, Lothar Bergmann, Michael Scheffler

Publikováno v: Oncology Research and Treatment. 42:57-66

Background: This study assessed the quality of life (QoL) and the implication of time effort of everolimus treatment in patients with metastatic renal cell carcinoma (mRCC). Methods: Adult patients with mRCC were eligible for everolimus treatment aft

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6e5caf7c7719b672664facd1d3e5505
https://doi.org/10.1159/000494278

Zobrazit plný text záznamu

Plný text ve formátu HTML

The EVERPRO study: Final results of a non-interventional study (NIS) evaluating the quality of life (QoL) in second-line treatment of metastatic renal cell carcinoma (mRCC) with everolimus

Autor: Anja Rogler, P. J. Goebell, K. Blumenstengel, Norbert Marschner, Christian Doehn, Ulrich Kube, Marc-Oliver Grimm, Lothar Bergmann, Edwin Herrmann, Anja Dietel, Michael Scheffler

Publikováno v: Journal of Clinical Oncology. 36:631-631

631 The EVERPRO study: Final results of a non-interventional study evaluating QoL in second-line treatment of mRCC with everolimus Background: Although the prognosis of mRCC patients remains poor, median overall survival has improved since 2006, prob

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::75be99a638457f0d987a4076816147eb
https://doi.org/10.1200/jco.2018.36.6_suppl.631

Zobrazit plný text záznamu

Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: final results of a noninterventional study

Autor: Joerg Schmitz, Michael Staehler, Steffen Weikert, Thomas Steiner, Edwin Herrmann, Lothar Bergmann, Peter J. Goebell, Michael Albrecht, Christian Doehn, Ulrich Kube, Jan Janssen, Michael Scheffler, Manfred Kindler

Publikováno v: BMC Cancer

Background Data are limited regarding routine use of everolimus after initial vascular endothelial growth factor (VEGF)–targeted therapy. The aim of this prospective, noninterventional, observational study was to assess efficacy and safety of evero

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::074491537962c21a5df11be189ac2b9d
https://doi.org/10.1186/s12885-015-1309-7

Zobrazit plný text záznamu

Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: results of a pooled analysis of non-interventional studies

Autor: Jean-Christophe Eymard, Laurence Albiges, Gernot Guderian, Nadia Kelkouli, Lothar Bergmann, Manuela Schmidinger, Ulrich Kube, Styliani Florini, Agnese Cattaneo, Aristotelis Bamias, Bernhard Mraz

Publikováno v: European journal of cancer (Oxford, England : 1990). 51(16)

Aim To assess the efficacy and safety of everolimus in patients with metastatic renal cell carcinoma (mRCC) who failed one or two anti-VEGF therapies. Patients and methods Data from four prospective, non-interventional studies conducted in Germany, F

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c40b8e7da178518e432fb5e30ec2b93
https://pubmed.ncbi.nlm.nih.gov/26276039

Zobrazit plný text záznamu

Therapy of mRCC beyond mTOR-inhibition in clinical practice : results of a retrospective analysis

Autor: Lothar Bergmann, Ulrich Kube, Viktor Grünwald, Luise Maute, Christoph Kahl, Thomas Gauler, Steffen Weikert, Iris Burkholder

Renal cell carcinoma (RCC) is the most common renal tumor and accounts for nearly 3 % of adult cancers. In the recent years, seven new targeted agents have been approved changing the treatment in metastatic RCC dramatically. So far, however, it remai

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3f5b62da39411c014e879db0a6f2e30
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=84901605959

Zobrazit plný text záznamu

Everolimus for Patients with Metastatic Renal Cell Carcinoma (Mrcc) Refractory to Anti-Vegf Therapy: Updated Results of a Pooled Analysis of Noninterventional Studies

Autor: C. Rose, Nadia Kelkouli, Lothar Bergmann, Agnese Cattaneo, S. Florini, Manuela Schmidinger, Aristotle Bamias, J.-C. Eymard, Bernhard Mraz, Ulrich Kube, L. Albiges Sauvin

Publikováno v: Annals of Oncology. 25:iv294

Aim: The pivotal RECORD-1 trial showed that the oral mTOR inhibitor everolimus significantly improved PFS compared with placebo in patients with mRCC refractory to 1 or 2 prior VEGFr-TKIs. Because clinical trial results may differ from clinical pract

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2a9731260dbaeb577ab3f332153e087a
https://doi.org/10.1093/annonc/mdu337.38

Zobrazit plný text záznamu

Everolimus as second-line therapy for metastatic renal cell carcinoma (mRCC) after one previous VEGF-targeted therapy: Final results of the noninterventional change study

Autor: Gernot Guderian, Thomas Steiner, Michael Albrecht, Edwin Herrmann, Jan Janssen, Michael Staehler, Steffen Weikert, Lothar Bergmann, Christian Doehn, Friedrich Overkamp, Michael Scheffler, Peter J. Goebell, Ulrich Kube, Joerg Schmitz, Manfred Kindler

Publikováno v: Journal of Clinical Oncology. 32:469-469

469 Background: The mTOR inhibitor everolimus is approved for the treatment of mRCC following failure of VEGF-targeted therapy. To evaluate the effectiveness and tolerability of everolimus following the first VEGF-targeted therapy in routine clinical

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::33783014c2ca6863c7c4e38690b4c803
https://doi.org/10.1200/jco.2014.32.4_suppl.469

Zobrazit plný text záznamu

Pooled Analysis of Non-Interventional Studies of Everolimus in Patients with Metastatic Renal Cell Carcinoma (MRCC) Refractory to Anti-VEGF Therapy

Autor: Gernot Guderian, Meryem Ktiouet, Lothar Bergmann, Manuela Schmidinger, Ulrich Kube, G. Fischer, J.-C. Eymard, Aristotle Bamias, D. Xanthaki, Laurence Albiges

Publikováno v: Annals of Oncology. 23:ix278

Background The oral mTOR inhibitor everolimus has demonstrated statistically significant PFS benefit over placebo in patients with mRCC refractory to 1 or 2 previous VEGFr-tyrosine kinase inhibitors. Here, we report prospective data on everolimus in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::14316e433f651ac00fbffb40bca8fa8c
https://doi.org/10.1016/s0923-7534(20)33412-8

Zobrazit plný text záznamu

Updated results of a prospective noninterventional study of everolimus after use of 1 VEGFR-TKI

Autor: Michael Staehler, Joerg Schmitz, Friedrich Overkamp, Manfred Kindler, Christian Doehn, Edwin Herrmann, Gernot Guderian, Gabriel Steiner, Susanne Kloss, Peter J. Goebell, Thomas Steiner, Ulrich Kube, Steffen Weikert, Lothar Bergmann, Andreas Jakob, Jan Janssen

Publikováno v: Journal of Clinical Oncology. 30:e15044-e15044

e15044 Background: Everolimus (EVE, Afinitor) is approved for the treatment of metastatic renal cell cancer (mRCC) after failure of VEGF-targeted therapy. The option to treat mRCC with six approved targeted agents has sparked debate on proper sequenc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::031265267b7bb2eb13fa3fdc5b04fb56
https://doi.org/10.1200/jco.2012.30.15_suppl.e15044

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání